Crizotinib
Orphan DrugFDA Approved
Contents
Description
Crizotinib is a tyrosine kinase inhibitor used to treat non-small cell lung cancer (NSCLC) with specific genetic mutations. It targets ALK and ROS1 kinases.
Indications & Therapeutic Use
ALK-positive non-small cell lung cancer, ROS1-positive non-small cell lung cancer
Linked Diseases:
hydrops fetalis
P56D015160
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Crizotinib — GNH India
22 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Rizonib 200mg
200capsuleINDIA
Rizonib 250mg
250mgcapsuleINDIA
Xalkori
200mgcapsuleGermany
Xalkori 250mg
250mgcapsuleS. Korea
Crizalk
250mgcapsuleGermany
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Crizotinib
| Generic Name | Crizotinib |
| Brands | 1 brand available |
| Active Ingredient | Crizotinib |
| Drug Class | ALK-positive non-small cell lung cancer |
| Manufacturer | Pfizer |
| Dosage Forms | Capsule, 200mg |
| Medical Code | L01XE16 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 10 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00585195 |
| Countries | 5 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations6 Validated Nodes